The participants in this study included patients from the Investigating Glaucoma Progression Study (IGPS), which is an ongoing prospective study that has been under way since August 2011 at the Seoul National University Bundang Hospital Glaucoma Clinic. The study protocol was reviewed and approved by the Seoul National University Bundang Hospital (SNUBH) Institutional Review Board. This study was carried out in accordance with the recommendations of the Declaration of Helsinki for biomedical research involving human subjects.
The database of patients included in the IGPS between January 2012 and May 2015 was reviewed. The subjects underwent a complete ophthalmic examination, including a visual acuity assessment, refraction, slit-lamp biomicroscopy, gonioscopy, Goldmann applanation tonometry, and dilated stereoscopic examination of the optic disc. They also underwent measurements of central corneal thickness (Orbscan II; Bausch & Lomb Surgical, Rochester, NY, USA) and axial length (AXL) (IOL Master version 5; Carl Zeiss Meditec, Dublin, CA, USA), corneal curvature (KR-1800; Topcon, Tokyo, Japan), stereo disc photography (EOS D60 digital camera; Canon, Utsunomiya-shi, Tochigi-ken, Japan), scanning of the optic disc and circumpapillary RNFL thickness measurements using spectral-domain optical coherence tomography (SD-OCT) (Spectralis OCT, Heidelberg Engineering, Heidelberg, Germany), and standard automated perimetry (24-2 Swedish interactive thresholding algorithm and Humphrey Field Analyzer II 750; Carl Zeiss Meditec).
The subjects included in the IPGS were required to have a best-corrected visual acuity of at least 20/40, spherical refraction of −6.0 to +3.0 diopters (D), and a cylinder correction of −3.0 to +3.0 D. Those with a history of ocular surgery other than cataract or glaucoma surgery, of intraocular diseases (e.g., diabetic retinopathy or retinal vessel occlusion), or of neurologic diseases (e.g., pituitary tumor) that could cause visual field deficits were excluded.
To be included in the present study, patients were required to be diagnosed with unilateral POAG and to have a clinically apparent PPA in at least one eye that was visible on an infrared fundus image with a width of ≥200 μm on at least one radial B-scan image as measured by the built-in caliper tool of the Spectralis OCT.
12 Eyes with poor image quality in which the clinical PPA was not delineated clearly on SD-OCT images were excluded. Subjects with a large PPA that exceeded the area covered by each radial scan were also excluded from this study.
Primary open-angle glaucoma was diagnosed according to the following criteria: an open angle on gonioscopy, glaucomatous optic nerve damage (e.g., the presence of focal thinning or notching of the neuroretinal rim, or diffuse thinning of the neuroretinal rim), and associated visual field defect without ocular disease or conditions that may cause visual field abnormalities. A glaucomatous visual field change was defined as being present when two or more of the following criteria were fulfilled: (1) outside the normal limits on the Glaucoma Hemifield Test; (2) three abnormal points with a probability of being normal of P < 5%, and one with P < 1% by pattern deviation; or (3) a pattern standard deviation of P < 5%. Those visual field defects were confirmed on two consecutive reliable tests (fixation loss rate ≤20%, false-positive and false-negative error rates ≤25%). The contralateral eye had to have an open angle on gonioscopy, a normal-appearing optic disc, and a normal visual field.
To exclude the influence of IOP, only patients with a diurnal IOP of consistently ≤21 mm Hg in both eyes were included in the study. Diurnal measurements of IOP were obtained every 2 hours from 9:00 AM to 5:00 PM, and the average of the five measurements was defined as the untreated IOP. The IOP at examination was defined as the IOP at the time of the SD-OCT imaging.